AMENDMENT NUMBER ONE TO THE EXCLUSIVE OPTION AGREEMENTExclusive License Agreement • August 7th, 2015 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS EXCLUSIVE LICENSE AGREEMENT (the “ Agreement ”), entered into effective as of June 12, 2015 (“ Effective Date ”), is by and between Memorial Sloan Kettering Cancer Center (“ MSK ”), a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, NY 10065, and Atara Biotherapeutics, Inc. (“ Licensee ”), a corporation with offices at 701 Gateway Blvd, Suite 200, South San Francisco, CA 94080. MSK and Licensee are sometimes referred to singly as “ Party ” and collectively as “ Parties .”
